Focused on oncology, WILEX develops diagnostic and therapeutic product
candidates based on antibodies, which are available for
out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract
research services and an antibody drug conjugate (ADC)
25.4.2016: WILEX AG successfully completes capital increase.
The Executive Management Board of WILEX AG today decided – with the Supervisory Board’s approval – to set the final scope of the rights issue to be executed to a total of 2,248,272 new shares. ...More
Seite gelesen: 473989 | Heute: 353